Pacritinib - Generic Drug Details
✉ Email this page to a colleague
Anatomical Therapeutic Chemical (ATC) Classes for Pacritinib
US Patents and Regulatory Information for Pacritinib
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sobi | VONJO | pacritinib citrate | CAPSULE;ORAL | 208712-001 | Feb 28, 2022 | RX | Yes | Yes | 8,153,632 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Sobi | VONJO | pacritinib citrate | CAPSULE;ORAL | 208712-001 | Feb 28, 2022 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Sobi | VONJO | pacritinib citrate | CAPSULE;ORAL | 208712-001 | Feb 28, 2022 | RX | Yes | Yes | 9,573,964 | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
